Welcome to our dedicated page for SeaStar Medical Holding news (Ticker: ICU), a resource for investors and traders seeking the latest updates and insights on SeaStar Medical Holding stock.
Overview of SeaStar Medical Holding Corp
SeaStar Medical Holding Corp is a specialized medical technology company focused on developing proprietary solutions to reduce the damaging consequences of hyperinflammation on vital organs. Operating within the realms of medical device innovation and immunomodulation, the company leverages extracorporeal therapies to target the key effector cells responsible for initiating and propagating imbalanced immune responses. Utilizing advanced biomedical research and development techniques, SeaStar addresses systemic inflammation, a crucial factor in various inflammatory conditions, by modulating and controlling excessive cytokine release.
Core Business and Technological Innovation
The company centers its business model on the development and commercialization of systems that provide extracorporeal therapeutic solutions. By isolating and targeting cells that contribute to tissue damage, SeaStar Medical focuses on mitigating the impact of hyperinflammation, a core issue in severe inflammatory responses. Its offerings are underpinned by years of research in the fields of immunology and medical technology, integrating concepts of immunomodulation and extracorporeal circulation to develop therapies that are both innovative and therapeutic. The company’s proprietary platforms are designed to work efficiently with existing clinical practices, elevating the standards of care and patient outcomes.
Extracorporeal Therapy Mechanism
At the heart of SeaStar Medical Holding Corp's technology is its approach to extracorporeal therapies. These systems are engineered to interact directly with the blood outside the body, effectively reducing the number and activity of pro-inflammatory effector cells without interfering with patients' normal physiological processes. This targeted approach helps to manage systemic inflammation by preventing the propagation of a harmful cytokine cascade that may lead to direct tissue injury. The technical sophistication of these methods reflects advanced knowledge in biomedicine and healthcare engineering, emphasizing safety and precise control over the immune response.
Market Position and Competitive Landscape
SeaStar Medical Holding Corp occupies a niche within the healthcare technology sector by focusing on the control of hyperinflammatory conditions through extracorporeal therapies. This specific emphasis allows the company to differentiate itself in a competitive market that spans biotech, medical devices, and immunotherapy. While competitors in the broader medical technology landscape may offer generalized treatment approaches, SeaStar Medical distinguishes its products by combining deep scientific research with innovative therapeutic platforms that target the cellular drivers of inflammation. Its strategic positioning is further enhanced by its commitment to scientific rigor and adherence to advanced regulatory standards.
Operational Considerations and Industry Relevance
The operational framework of SeaStar Medical is built upon extensive research and the integration of interdisciplinary scientific expertise, ensuring that its technology is both effective and safe. Operating within a highly regulated environment, the company maintains a concentrated focus on developing therapies that meet rigorous medical and quality control standards. The strategic intersection of immunology, biomedical engineering, and clinical research facilitates the development of therapies that have clear applications in addressing systemic inflammatory conditions. This niche focus supports a long-term commitment to improving patient care without overstating financial metrics or employing speculative forecasts.
Scientific and Clinical Expertise
SeaStar Medical Holding Corp is recognized for its scientific foundations and clinical insights, which are integral to the design and deployment of its extracorporeal systems. The company’s approach is built on a comprehensive understanding of inflammatory pathways, employing detailed analysis of cytokine dynamics and immune cell activities. Such expertise ensures that each technological advancement is measured against stringent clinical benchmarks and relevant scientific standards, thereby reinforcing the company’s credibility among healthcare professionals and researchers.
Strategic Communication of Innovation and Safety
The company’s communication strategy emphasizes clear, authoritative information regarding the mechanisms behind its treatments and the benefits of its technologies. By discussing concepts such as immunomodulation and extracorporeal therapy in accessible language, SeaStar Medical effectively informs stakeholders about both the complexity and the clinical relevance of its innovations. Each section of its communication is designed to enhance understanding and foster confidence in its scientific rigor, without providing speculative commentary on future outcomes.
Conclusion
In summary, SeaStar Medical Holding Corp stands out as a focused medical technology enterprise dedicated to mitigating the impact of hyperinflammation via advanced extracorporeal therapies. Its niche approach underpinned by robust scientific research and a commitment to high clinical standards positions it as a significant player within a specialized segment of the medical device and biotech industries. The company’s detailed and transparent operational model, combined with its clear focus on patient safety and scientific precision, ensures a balanced and expert perspective on its contributions to the field of immunomodulation and systemic inflammation control.
SeaStar Medical (Nasdaq: ICU) reported its Q4 and full-year 2024 financial results, marking significant progress in its commercial and clinical initiatives. The company achieved $0.1 million in net revenue for 2024, following the FDA approval and launch of QUELIMMUNE therapy for pediatric acute kidney injury patients.
Key highlights include: enrollment of 94 out of 200 patients in the NEUTRALIZE AKI pivotal trial, securing a fourth Breakthrough Device Designation, and adoption of QUELIMMUNE by five customers. The company raised approximately $31 million in capital and reduced debt.
Financial results show R&D expenses increased to $9.1 million from $6.0 million in 2023, while G&A expenses rose to $8.9 million from $8.2 million. The company reported a net loss of $24.8 million ($6.63 per share) compared to $26.2 million ($30.26 per share) in 2023. Cash position stood at $1.8 million as of December 31, 2024, with an additional $6 million raised in February 2025.
SeaStar Medical Holding (Nasdaq: ICU), a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025, after market close.
The company will host a webcast and conference call to discuss the results and business progress. A replay will be available until April 3, 2025, accessible via webcast or by calling 1 (609) 800-9909.
SeaStar Medical (Nasdaq: ICU) has been awarded the 2025 Corporate Innovator Award from the National Kidney Foundation for their groundbreaking QUELIMMUNE Selective Cytopheretic Device. The device received FDA approval in February 2024 as the first therapeutic solution for treating pediatric Acute Kidney Injury (AKI) due to sepsis.
Each year, approximately 4,000 children with AKI in the U.S. require continuous kidney replacement therapy, facing a 50% mortality rate. Of those who survive, 10-25% experience long-term complications including chronic kidney disease and lifetime dialysis dependency.
The award will be presented during the NKF Spring Clinical Meetings in Boston from April 9-13, 2025. This recognition places SeaStar Medical among notable past recipients including Keryx Biopharmaceuticals, Janssen Pharmaceuticals, Merck, Otsuka Pharmaceuticals, Relypsa, and UnitedHealth Group.
SeaStar Medical (Nasdaq: ICU) has closed a previously announced registered direct offering priced at-the-market, raising $6 million in gross proceeds. The offering included 3,529,412 shares of common stock (or pre-funded warrants) at $1.70 per share to a single institutional investor.
The transaction included warrants for an additional 3,529,412 shares in a concurrent private placement. The pre-funded warrants have a $0.001 exercise price with no expiration, while the additional warrants have a $1.70 exercise price, exercisable upon shareholder approval with a five-year term. The company plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures. H.C. Wainwright & Co. served as the exclusive investment bank for the offering.
SeaStar Medical (Nasdaq: ICU) has announced a $6 million registered direct offering with a single institutional investor. The offering includes 3,529,412 shares of common stock (or pre-funded warrants) at $1.70 per share, along with warrants to purchase an additional 3,529,412 shares in a concurrent private placement.
The pre-funded warrants will have a $0.001 exercise price with immediate exercisability, while the additional warrants will have a $1.70 exercise price, exercisable upon shareholder approval with a five-year expiration. The offering is expected to close around February 3, 2025.
The company plans to use the net proceeds for general corporate purposes, including working capital and capital expenditures. H.C. Wainwright & Co. is serving as the exclusive financial advisor for this offering.
SeaStar Medical (Nasdaq: ICU) has expanded its customer base by shipping QUELIMMUNE™ to a fifth hospital, a California medical center known for pediatric research. QUELIMMUNE, their Selective Cytopheretic Device (SCD), treats critically ill children in ICU with acute kidney injury (AKI) and sepsis.
The company is actively pursuing additional hospital clearances through institutional review board (IRB) approvals, with more than a dozen new medical centers in discussion and seven advancing in the IRB process. Several existing customers have already placed reorders in 2025.
QUELIMMUNE operates under FDA approval through a Humanitarian Device Exemption for children weighing 10kg or more requiring renal replacement therapy. The device uniquely targets proinflammatory neutrophils and monocytes during continuous renal replacement therapy, potentially promoting long-term organ recovery and eliminating future dialysis needs. The SCD has received FDA Breakthrough Device Designation in four indications.
SeaStar Medical (Nasdaq: ICU) has activated its 15th site, Mayo Clinic, for the NEUTRALIZE-AKI pivotal trial, which is evaluating the safety and efficacy of its Selective Cytopheretic Device (SCD) in treating acute kidney injury (AKI). The trial has currently enrolled 76 subjects, with 6 new enrollments since the start of 2024.
The study aims to evaluate 200 adults with AKI in ICU receiving continuous renal replacement therapy (CRRT). The primary endpoint focuses on 90-day mortality or dialysis dependency compared to standard CRRT care. The company expects a Data Safety Monitoring Board recommendation on interim results by mid-2025 after analyzing the first 100 subjects.
The SCD, which has FDA Breakthrough Device Designation for adults with AKI, targets proinflammatory neutrophils and monocytes during CRRT to reduce hyperinflammation. SeaStar Medical estimates the annual U.S. market opportunity for SCD in adult AKI at $4.7-6.3 billion.
SeaStar Medical (Nasdaq: ICU) received FDA approval for an investigational device exemption (IDE) to study their Selective Cytopheretic Device (SCD-ADULT) in reducing inflammation in adult patients with acute heart failure and worsening renal function. The feasibility study will enroll 20 patients across up to five clinical sites, funded by a $3.6 million NIH grant awarded to Innovative BioTherapies.
The study will be led by SCD inventor Dr. H. David Humes, with SeaStar Medical acting as clinical research organization. The device received Breakthrough Device Designation from FDA's CBER in September 2023 for cardiorenal syndrome with LVAD. The company estimates the total addressable U.S. market for SCD-ADULT in cardiorenal syndrome at over $1 billion annually.
SeaStar Medical (Nasdaq: ICU) has expanded its commercial reach by shipping its QUELIMMUNE™ device to a fourth hospital customer, a prominent academic medical center. QUELIMMUNE is a Selective Cytopheretic Device (SCD) designed to treat critically ill children in ICU with acute kidney injury (AKI) and sepsis.
The device, approved by FDA under Humanitarian Device Exemption, has shown clinical benefits in reducing mortality and decreasing dialysis dependency. According to company data, AKI patients treated with SCD showed no dialysis dependency 60 days post-treatment, potentially saving approximately $100,000 per patient annually in dialysis costs. The average hospital cost per pediatric ICU patient with AKI requiring continuous renal replacement therapy exceeds $350,000.
QUELIMMUNE is approved for children weighing 10 kilograms or more who require renal replacement therapy. The SCD technology uniquely targets proinflammatory neutrophils and monocytes during continuous renal replacement therapy, potentially promoting long-term organ recovery.
SeaStar Medical (Nasdaq: ICU) has activated its 14th hospital site for the NEUTRALIZE-AKI pivotal trial, evaluating their Selective Cytopheretic Device (SCD) in acute kidney injury patients. Currently, 70 of 200 planned subjects are enrolled, with 24 in Q4. The company expects Data Safety Monitoring Board interim results by mid-2025 after the first 100 subjects complete the 90-day primary endpoint.
The company estimates the U.S. addressable market for SCD in adult AKI at $4.7-6.3 billion, with trial costs around $15 million. The SCD has FDA Breakthrough Device Designation for adults with AKI, and received Category B coverage from CMS for certain expenses in July 2024. The trial's primary endpoint focuses on 90-day mortality or dialysis dependency comparing SCD plus CRRT versus CRRT alone.